A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.

Sci Rep · 2019 · PMC6367406 · PMID 30733547

Europe PMC DOI

hedged sentences

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significanceP = 0.057so close (0.05 < p ≤ 0.1)

Also, patients with IM+/CLDN-high tumors had a better prognosis than those with IM−/CLDN−, although these differences did not reach statistical significance (HR, 0.3556; 95% CI 0.04115–0.9828; P = 0.057).

also in 111,027 other papers

showed a trendno p-value reported

CLDN-high tumors showed a trend toward a poorer prognosis than CLDN-low, but again, the differences were not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.